MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies
Hematologic Malignancy|Acute Leukemia|Remission|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|AML|TP53|Intrachromosomal Amplification of Chromosome 21|Cytogenetic Abnormality|CNS Leukemia|Minimal Residual Disease|Myelodysplasia|Juvenile Myelomonocytic Leukemia|Somatic Mutation|PTPN11 Gene Mutation|N-RAS Gene Amplification|Neurofibromatosis 1|NF1 Mutation|CBL Gene Mutation|Monosomy 7|Chromosome Abnormality|Fetal Hemoglobin
DRUG: Fludarabine|DRUG: Busulfan|DRUG: Melphalan|DRUG: Rituximab|DRUG: Levetiracetam
Determine the rate of GVHD after alpha beta TCR depletion, GVHD incidence after treatment., 85 months
Transplant engraftment, Monitor median rate of engraftment by 42 days., 42 days|Graft Failure, Determine the rate of graft failure by day 100 (defined as lack of achievement of an ANC \>=500/mL with associated pancytopenia), 100 days|Non-relapse mortality (NRM), Determine the incidence of non-relapse mortality (NRM) at 100 days and 1 year, 12 months|Overall survival (OS), Number of participants experiencing progression free survival at one year follow up, 12 months
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies